Testosterone replacement therapy (TRT) significantly reduces semen production in most men through suppression of the hormones essential for sperm development. This effect occurs because exogenous testosterone triggers a negative feedback mechanism that decreases luteinising hormone (LH) and follicle-stimulating hormone (FSH), both crucial for testicular function and spermatogenesis. Whilst this suppression is generally reversible after stopping treatment, recovery timelines vary considerably between individuals. Men of reproductive age considering testosterone therapy should receive comprehensive fertility counselling beforehand, including discussion of sperm banking and alternative treatments that preserve fertility whilst managing hypogonadism symptoms.

How Testosterone Treatment Affects Semen Production

Testosterone replacement therapy (TRT) significantly reduces semen production in most men, often leading to oligospermia (low sperm count) or azoospermia (absence of sperm in ejaculate). This effect occurs through a well-established mechanism involving the hypothalamic-pituitary-gonadal (HPG) axis. When exogenous testosterone is administered—whether via injections, gels, patches, or implants—the body detects elevated testosterone levels in the bloodstream.

This detection triggers a negative feedback loop at the hypothalamus and pituitary gland. The hypothalamus reduces its secretion of gonadotrophin-releasing hormone (GnRH), which in turn causes the pituitary to decrease production of luteinising hormone (LH) and follicle-stimulating hormone (FSH). These two hormones are essential for testicular function: LH stimulates the Leydig cells to produce testosterone locally within the testes, whilst FSH is crucial for spermatogenesis (sperm production) by supporting Sertoli cells.

When LH and FSH levels drop substantially, the testes receive insufficient stimulation to maintain normal sperm production. Most men on testosterone therapy experience marked suppression of sperm count, with azoospermia commonly developing within months of treatment initiation. The degree of suppression varies between individuals and depends on factors including dosage, duration of treatment, baseline fertility status, and individual physiological response.

It is important to note that whilst semen volume may also decrease to some extent, the primary concern relates to sperm concentration and total sperm count rather than ejaculate volume itself. Men may continue to ejaculate but with dramatically reduced or absent sperm content, making natural conception difficult or impossible during treatment. TRT should generally not be initiated in men actively trying to conceive, and fertility options should be discussed with a specialist first.

Fertility Considerations Before Starting Testosterone

Before commencing testosterone therapy, all men of reproductive age should receive comprehensive counselling about fertility implications. This discussion should occur regardless of whether the patient currently plans to have children, as future family planning intentions may change.

Key considerations include:

• Current fertility status: Men concerned about future fertility should consider baseline semen analysis before starting treatment. This establishes a reference point and identifies any pre-existing fertility issues that might complicate future conception attempts.

• Sperm banking (cryopreservation): For men who may wish to father children in the future, sperm banking offers a reliable option to preserve fertility. This involves collecting and freezing sperm samples before testosterone therapy begins. Sperm banking may be available via the NHS in specific circumstances; otherwise, private fertility clinics offer this service. Discuss funding and eligibility with your GP or local fertility services.

• Partner discussions: Men in relationships should involve their partners in fertility discussions, as reproductive decisions affect both individuals. Joint consultations with fertility specialists may be beneficial.

• Timeline considerations: Testosterone's suppressive effects on semen production typically begin within weeks to months of treatment initiation. Delaying treatment to complete family planning or arrange sperm banking may be appropriate in some cases.

Healthcare professionals should document these discussions thoroughly and ensure patients understand that testosterone therapy is not a reliable contraceptive method, despite reducing fertility. Pregnancy remains possible, particularly in the early treatment phases or with inconsistent testosterone use. Men should continue using appropriate contraception if pregnancy prevention is desired.

If you have concerns about fertility, discuss with your GP who can refer you to endocrinology, andrology or NHS fertility services as appropriate. Regular review of fertility intentions should occur during ongoing testosterone therapy, as circumstances and priorities may evolve over time.

Reversibility of Testosterone Effects on Semen

The suppression of semen production caused by testosterone therapy is generally reversible, though recovery is neither guaranteed nor immediate. Research indicates that most men will experience some degree of spermatogenesis recovery after discontinuing testosterone, but the timeline and extent of recovery vary considerably between individuals.

Recovery typically follows this pattern: After stopping testosterone therapy, the HPG axis gradually reactivates. The hypothalamus resumes GnRH secretion, prompting the pituitary to increase LH and FSH production. These hormones then stimulate the testes to resume testosterone production and spermatogenesis. This process takes time—sperm production may begin to recover within 3–6 months, but most men recover towards baseline within 12 months, with some taking longer.

Several factors influence recovery prospects:

• Duration of testosterone use: Longer treatment periods (particularly beyond 12–24 months) may be associated with slower or incomplete recovery, though there is no absolute threshold beyond which recovery becomes impossible.

• Age: Younger men generally demonstrate better recovery potential than older men, whose baseline testicular function may already be declining.

• Baseline fertility: Men with normal pre-treatment fertility typically recover better than those with pre-existing fertility issues.

• Dosage and formulation: Higher doses and longer-acting preparations may require extended recovery periods.

Important limitations exist: A minority of men may experience prolonged suppression or incomplete recovery of fertility even after stopping testosterone. There is no guarantee of complete recovery in all cases. Men who have been on testosterone therapy for several years should be counselled that recovery may be partial or take considerably longer than average.

Specialist referral to an endocrinologist or andrologist is advised if fertility has not recovered by 12 months after stopping TRT or for men with pre-existing infertility. Some specialists may consider treatments such as human chorionic gonadotrophin (hCG) or selective oestrogen receptor modulators (SERMs) to stimulate testicular function, though these uses are generally off-label in the UK and should only be managed by specialists.

Alternative Treatments That Preserve Fertility

For men requiring treatment for hypogonadism who wish to preserve fertility, several alternative approaches exist that can improve testosterone levels and symptoms whilst maintaining or even enhancing semen production. These options work by stimulating the body's own testosterone production rather than suppressing it through exogenous hormone administration.

Human chorionic gonadotrophin (hCG) mimics the action of LH, directly stimulating the Leydig cells in the testes to produce testosterone. When used alone or in combination with FSH or human menopausal gonadotrophin (hMG), hCG can maintain intratesticular testosterone levels sufficient for spermatogenesis whilst improving serum testosterone. This approach requires subcutaneous injections, typically administered multiple times weekly. In the UK, gonadotrophin therapy for male hypogonadism is specialist-initiated and requires careful monitoring.

Selective oestrogen receptor modulators (SERMs), such as clomifene citrate, offer an oral alternative. These medications block oestrogen receptors in the hypothalamus and pituitary, preventing the negative feedback that oestrogen (converted from testosterone) normally exerts. This results in increased GnRH, LH, and FSH secretion, stimulating the testes to produce more testosterone and maintain spermatogenesis. It is important to note that clomifene is not licensed for use in men in the UK and is prescribed off-label under specialist supervision.

Aromatase inhibitors, such as anastrozole, work by blocking the conversion of testosterone to oestrogen, thereby reducing oestrogen-mediated negative feedback and increasing gonadotrophin secretion. These medications are also used off-label for men in the UK, and evidence supporting their use for hypogonadism is less robust than for other approaches.

Important considerations: These fertility-preserving treatments may not achieve testosterone levels as high as conventional TRT, and symptom improvement may be less pronounced in some men. They require specialist initiation and monitoring. They are not suitable for all causes of hypogonadism, particularly primary testicular failure. Treatment decisions should be individualised based on patient priorities, fertility goals, and underlying cause of hypogonadism. Men should discuss these options with endocrinologists or fertility specialists to determine the most appropriate approach for their circumstances.

Frequently Asked Questions